Therapeutic methods for inhibiting tumor growth with Dll4 antagonists

Details for Australian Patent Application No. 2006326417 (hide)

Owner Regeneron Pharmaceuticals, Inc.

Inventors Smith, Eric; Thurston, Gavin; Noguera, Irene; Gale, Nicholas

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2006326417

PCT Pub. Number WO2007/070671

Priority 60/771,276 08.02.06 US; 60/751,173 16.12.05 US; 60/830,543 12.07.06 US; 60/788,456 31.03.06 US

Filing date 15 December 2006

Wipo publication date 21 June 2007

Acceptance publication date 24 May 2012

International Classifications

A61K 39/00 (2006.01) Medicinal preparations containing antigens or antibodies

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

19 June 2008 PCT application entered the National Phase

  PCT publication WO2007/070671 Priority application(s): WO2007/070671

24 May 2012 Application Accepted

  Published as AU-B-2006326417

20 September 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006326418-Non-natural amino acids and neurotensin analogues thereof

2006326405-Scaffolds for cell transplantation